At this time, New York Oncology Hematology does not have access to acquire and administer the new COVID prophylaxis shot Evusheld for immunocompromised patients. We await further guidance from NYS and will keep our patients updated.

Clinical Trials & Research

GU-102 Ph I/II Nivo + axitinib RCC

Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

Disease Types: Renal,&nbs

Available at: {clinical_trial_location backspace="7"}GU-102 Ph I/II Nivo + axitinib RCC, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}